Twenty-Four Month Clinical Outcomes Of Istent Inject®Trabecular Micro-Bypass Glaucoma Surgery In West Of Scotland
Published 2023 - 41st Congress of the ESCRS
Reference: PO0866 | DOI: 10.82333/kjzs-cc10
Authors: Thomas Siempis 1 , Jonathan Nairn* 2 , Andrew Inglis 1 , Mamun Rahman 2 , Andreas Syrogiannis 1
1Ophthalmology,University Ayr Hospital,Ayr,United Kingdom, 2Ophthalmology,Tennent Institute of Ophthalmology,Glasgow,United Kingdom
The aim of this audit was to evaluate the clinical outcomes and safety profile of the iStent Inject®Trabecular Micro-bypass in West of Scotland over a period of 3 years.
2 glaucoma units in West of Scotland (University Ayr Hospital in Ayr and New Victoria Hospital in Glasgow, UK).
Retrospective audit examining cases of iStent Inject® implantation at University Ayr Hospital in Ayr and New Victoria Hospital in Glasgow by three glaucoma specialists between 2018 and 2021. The level of significance was set at p<0.05 (Wilcoxon Rank test).
128 eyes were identified. 85.3% of the eyes had combined cataract surgery and iStent Inject® implantation. Mean pre-operative IOP was 21.6mmHg (SD:6.7, n=128), decreasing to 14.8mmHg at 3 months (SD:4.6, n=70), 15.2mmHg at 6 months (SD:4.4, n=46), 15.8 mmHg at 12 months (SD:4.3, n=71) and 15.4mmHg at 24 months (SD:3.6, n =34). The mean number of IOP lowering medications reduced from 2.5 at baseline (SD:1.2, n=128) to 1.6 at 12 months (SD:1.2, n = 70) and 1.4 (SD:1.3, n=33) in year 2 (p<0.05 for all time points both for IOP and number of drops). There were no intra-operative complications.
The above real word data shows that of iStent Inject® produces a clinically and statistically significant reduction in IOP in year 1 and 2 alongside a drop in the number of IOP lowering drops used and a very good safety profile.